BCL2 and lung carcinoma: This discovery has revealed the potential application value of Ligusticum chuanxiong in the treatment of lung cancer, and also provided new ideas for studying the role of the apoptotic pathway in lung cancer.The latest research indicates that the NADPH oxidase inhibitor roboxin (AP) can significantly reduce the survival ability of lung cancer A549 cells, induce cell apoptosis, and simultaneously increase the expression of Bax and Caspase-3, while reducing the expression of Bcl-2 [24].